Lead Product(s): Human antibodies
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: Discovery Platform Product Type: Large molecule
Deal Size: $90.0 million Upfront Cash: $90.0 million
Deal Type: Acquisition November 18, 2020
The acquisition deepens AbCellera’s technology stack with a suite of genetically engineered mice for generating diverse panels of human antibodies with drug-like properties.